Articles
In this issue of The Oncology Pharmacist, we feature an article on the new—and often misunderstood—world of biosimilars
A review of the incidence and management of hypersensitivity reactions to oxaliplatin revealed that many patients are unnecessarily taken off this important drug.
By Wayne Kuznar
The most recent update of the National Comprehensive Cancer Network (NCCN) guideline on breast cancer has undergone a number of “tweaks” with few major changes.
CancerLinQ (Learning Intelligence Network for Quality) is a powerful database containing a vast amount of usable, searchable, real-world cancer information, created by oncologists, for oncologists, to improve the quality of patient care, according to updates presented at the 2016 American Society of Clinical Oncology (ASCO) Quality Care Symposium.
By Wayne Kuznar
Achieving balance in the appropriate use of opioids to treat cancer pain requires skill and compassion.
Lymphomas, cancers that begin in lymphatic cells of the immune system, can be divided into 2 main categories: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
The key arguments supporting the use of combination therapy with checkpoint blockade immunotherapies as the standard of care for treating metastatic melanoma arise from the combination’s high disease control rates; rapid deep responses; improved response rates; longer progression-free survival (PFS); and good estimated overall survival (OS), approaching 70% at 3 years, said Steven J. O’Day, MD, Professor of Medical Oncology, John Wayne Cancer Institute at Providence Saint John’s Health Center, Santa Monica, CA, at the recent HemOnc Today Melanoma and Cutaneous Malignancies meeting.
By Wayne Kuznar
An updated survivorship guideline from the National Comprehensive Cancer Network (NCCN) includes an extensive revision on addressing sexual function in cancer survivors.
Physicians need to advocate for molecular profiling, according to Howard “Skip” Burris III, MD.